Primary angioplasty in myocardial infarction trial

Stone GW, Cox D, Gracia E, et al. Normal flow (TIMID) before mechanical reperfusion therapy is an independent determinant of survival in acute myocardial infarction results from the primary angioplasty in myocardial infarction trials. Circulation 2002 104 636-641. 

Brodie BR, Stone GW, Morice MC, Cox DA, Garcia E, Mattos LA, Boura J, O Neill WW, Stuckey TD, Milks S, Lansky AJ, Grines CL. Stent Primary Angioplasty in Myocardial Infarction Study Group. Importance of time to reperfusion on outcomes with primary coronary angioplasty for acute myocardial infarction (results from the Stent Primary Angioplasty in Myocardial Infarction Trial). Am J Cardiol 2001 88 1085-1090. 

DeGeare VS, Stone GW, Grines L, et al. Angiographic and clinical characteristics associated with increased in-hospital mortality in elderly patients with acute myocardial infarction undergoing percutaneous intervention a pooled analysis of the primary angioplasty in myocardial infarction trials. Am J Cardiol 2000 86 30-34. 

Acute infarct artery PCI was demonstrated initially to be feasible in conjunction with intracoronary thrombolysis in a small registry study reported in 1982 (43). The approach evolved quickly to one in which the intracoronary thrombolysis component was abandoned. The separation of mechanical and pharmacological approaches was reinforced by results in a small (56-patient), but very influential, randomized trial comparing primary PCI with administration of intracoronary streptokinase in 1986 (44). Primary PCI led to greater recovery of left ventricular function. Results from another relatively small, randomized trial (n = 142) were concordant. They demonstrated greater recovery of left ventricular function with primary PCI compared with intravenous streptokinase (45). The Primary Angioplasty in Myocardial Infarction... 

Stone GW, Grines CL, Browne KF, et al. Predictors of in-hospital and 6-month outcome after acute myocardial infarction in the reperfusion era The Primary Angioplasty in Myocardial Infarction (PAMI) trial. J Am Coll Cardiol 1995 25 370-377. 

Nunn CM, O Neill WW, Rothbaum D, et al. for the Primary Angioplasty in Myocardial Infarction I study group. Long-term outcome after primary angioplasty report from the Primary Angioplasty in Myocardial Infarction (PAMI-1) trial. J Am Coll Cardiol 1999 33 640-646. 

Grines CL, Westerhausen DR, Grines LL, et al. A randomized trial of transfer for primary angioplasty versus on-site thrombolysis in patients with high-risk myocardial infarction the Air Primary Angioplasty in Myocardial Infarction Study. J Am Coil Cardiol 2002 39 1713-1719. 

In the only comparable U.S. trial of such a strategy, the Air Primary Angioplasty in Myocardial Infarction (AIR PAMI) study, door-to-balloon times were 155 minutes, including 35 minutes from presentation to randomization. Unfortunately, this promising study was terminated early secondary to slow patient accrual. Point estimates favoring transfer for primary PCI over on-site fibrinolysis were seen among the 138 patients who were randomized, with major adverse cardiac events (death, reinfarction, or stroke) occurring in 8.4% of patients treated with PCI versus 13.6% of patients treated with fibrinolysis... 

Grinfeld L, Berrocal D, Belardi J, et al. Eibrinolytics vs. primary angioplasty in acute myocardial infarction (EAP) a randomized trial in a community hospital in Argentina. J Am CoU Cardiol 1996 27 (supplA) 222A. 

Granger CB, Mahaffey KW, Weaver WD, Theroux P, Hochman JS, Filloon TG, Rollins S, Todaro TG, Nicolau JC, Ruzyllo W, Armstrong PW. Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial. Circulation. 2003 108 1184-1190. 

Liem A, Zijlstra F, Ottervanger JP, Hoomtje JC, Suryapranata H, de Boer MJ, Verheugt FW. High dose heparin as pretreatment for primary angioplasty in acute myocardial infarction the Heparin in Early Patency (HEAP) randomized trial. J Am Coll Cardiol 2000 35(3) 600-604. 

Tcheng JE, Kandzari DE, Grines CL, Cox DA, Effron MB, Garcia E et al. Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. Circulation 2003 108(ll) 1316-23. 

Stone GW, Grines CL, Cox DA, et al, Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 2002 346 957. Antoniucci D, Rodriguez A, Hempel A, et al, A randomized trial comparing primary infarct artery stenting with or without abciximab in acute myocardial infarction, J Am Coll Cardiol 2003 42 1879. 

Ross AM, Coyne KA, Reiner JS et al. A randomized trial comparing primary angioplasty with a strategy of short-acting fibrinolysis and immediate planned rescue angioplasty in acute myocardial infarction the PACT trial. J Am Coll Cardiol. 1999 34 1954-1962. 

In the UAE, as well as many countries in western Europe and North America, primary PCI for treatment of patients with STEMI was and still is not readily available in many hospitals. We believe the case for performing primary PCI in most such patients is not yet compelling. The impact of time to treatment on mortality after prehospital thrombolysis or primary angioplasty (CAPTIM study) has shown that prehospital thrombolysis may be preferable to primary PCI for patients treated within the first 2 hours after onset of symptoms. Conversely, the DANish Multi-Center Randomized Study on Eibrinoljdic Therapy versus Acute Myocardial Infarction (DANAMI-2) report showed a reduction in cardiac events in patients treated with primary angioplasty compared with those treated with fibrinolytic agents for STEMI (13,14). The critics of that study have pointed out that the trial included only 37% of the population with STEMI and excluded patients with... 

Antoniucci D, Santoro GM, Bolognese L, et al. A clinical trial comparing primary stenting of the infarct-related artery with optimal primary angioplasty for acute myocardial infarction results from the Horence Randomized Elective Stenting in Acute Coronary Occlusions (FRESCO) trial. J Am CoU Cardiol 1998 31 1234-1239. 

---